- Home
- SST vs ABP Comparison
SST vs ABP Comparison
Compare SST & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- ABP
- Stock Information
- Founded
- SST 2013
- ABP 2004
- Country
- SST United States
- ABP United States
- Employees
- SST N/A
- ABP N/A
- Industry
- SST Diversified Commercial Services
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- SST Consumer Discretionary
- ABP Health Care
- Exchange
- SST Nasdaq
- ABP Nasdaq
- Market Cap
- SST 67.8M
- ABP 26.5M
- IPO Year
- SST N/A
- ABP N/A
- Fundamental
- Price
- SST $0.46
- ABP $0.47
- Analyst Decision
- SST Buy
- ABP Strong Buy
- Analyst Count
- SST 2
- ABP 1
- Target Price
- SST $3.50
- ABP $4.00
- AVG Volume (30 Days)
- SST 144.3K
- ABP 55.7K
- Earning Date
- SST 03-10-2025
- ABP 03-21-2025
- Dividend Yield
- SST N/A
- ABP N/A
- EPS Growth
- SST N/A
- ABP N/A
- EPS
- SST N/A
- ABP N/A
- Revenue
- SST $343,925,000.00
- ABP $230,000.00
- Revenue This Year
- SST $8.34
- ABP N/A
- Revenue Next Year
- SST N/A
- ABP N/A
- P/E Ratio
- SST N/A
- ABP N/A
- Revenue Growth
- SST N/A
- ABP N/A
- 52 Week Low
- SST $0.42
- ABP $0.45
- 52 Week High
- SST $2.73
- ABP $13.00
- Technical
- Relative Strength Index (RSI)
- SST 34.30
- ABP N/A
- Support Level
- SST $0.45
- ABP N/A
- Resistance Level
- SST $0.58
- ABP N/A
- Average True Range (ATR)
- SST 0.06
- ABP 0.00
- MACD
- SST -0.00
- ABP 0.00
- Stochastic Oscillator
- SST 14.59
- ABP 0.00
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.